ERBB2 and neoplasm: For the 19 patients with a tumor type other than breast or oesogastric adenocarcinoma, the median PFS was 4.6 months CI95% [0.7–8.6]; for patients with ERRB2 mutations the median PFS was 2.9 months CI95% [2.4–3.3] and for patients with ERBB2 amplification the median PFS was 6.5 months CI95% [2–11], without statistical difference in PFS relative to amplifications or mutations (p = 0.4, Figure 4).